Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: Rare resistance is overcome by blocking interferon pathways

Journal of Virology

Volumn 85, Issue 18, 2011, Pages 9346-9358

  Paglino, Justin C ^a   van den Pol, Anthony N ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; GREEN FLUORESCENT PROTEIN; INTERFERON; JANUS KINASE 1; NUCLEIC ACID BINDING PROTEIN; ONCOLYTIC VESICULAR STOMATITIS VIRUS RP30A; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; VACCINIA VACCINE; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CARCINOMA; CANCER INHIBITION; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CELL DEATH; CELL KILLING; CHROMOSOME ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLYSIS; CYTOMEGALOVIRUS; DOWN REGULATION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; EWING SARCOMA; FIBROSARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION RATE; INFECTION RESISTANCE; LIPOSARCOMA; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OSTEOSARCOMA; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN METABOLISM; RHABDOMYOSARCOMA; SARCOMA; SIGNAL TRANSDUCTION; SINDBIS VIRUS; SYNOVIAL SARCOMA; TUMOR XENOGRAFT; VESICULAR STOMATITIS VIRUS; VIRUS ATTACHMENT; VIRUS ATTENUATION; VIRUS ENTRY; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; BIOMETRY; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; INTERFERONS; MICE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PATHOLOGY; RODENT DISEASES; SARCOMA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VESICULOVIRUS;

HUMAN HERPESVIRUS 5; MUS; SINDBIS VIRUS; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 80052475970     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00723-11     Document Type: Article

References (50)

1. Agarwalla, P. K., Z. R. Barnard, and W. T. Curry, Jr. 2010. Virally mediated immunotherapy for brain tumors. Neurosurg. Clin. N. Am. 21:167-179. doi: 10.1016/j.nec.2009.08.013.
2. Alcami, A., J. A. Symons, and G. L. Smith. 2000. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J. Virol. 74:11230-11239.
3. Bandi, P., N. E. Pagliaccetti, and M. D. Robek. 2010. Inhibition of type III interferon activity by orthopoxvirus immunomodulatory proteins. J. Interferon Cytokine Res. 30:123-134. doi:10.1089/jir.2009.0049.
4. Barber, G. N. 2004. Vesicular stomatitis virus as an oncolytic vector. Viral Immunol. 17:516-527. doi:10.1089/vim.2004.17.516.
5. Basagoudanavar, S. H., et al. 2011. Distinct roles for the NF-B RelA subunit during antiviral innate immune responses. J. Virol. 85:2599-2610. doi:10.1128/JVI.02213-10.
6. Berman, J. J. 2004. Tumor classification: molecular analysis meets Aristotle. BMC Cancer 4:10. doi:10.1186/1471-2407-4-10.
7. Bharatan, N. S., M. A. Currier, and T. P. Cripe. 2002. Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replicationcompetent herpes simplex viruses. J. Pediatr. Hematol. Oncol. 24:447-453.
8. Bridle, B. W., et al. 2010. Potentiating cancer immunotherapy using an oncolytic virus. Mol. Ther. 18:1430-1439. doi:10.1038/mt.2010.98.
9. Carey, B. L., M. Ahmed, S. Puckett, and D. S. Lyles. 2008. Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J. Virol. 82:12104-12115. doi:10.1128/ JVI.01508-08.
10. Connor, J. H., C. Naczki, C. Koumenis, and D. S. Lyles. 2004. Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo. J. Virol. 78:8960-8970. doi:10.1128/JVI.78.17.8960-8970.2004.
11. Diallo, J. S., et al. 2010. A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol. Ther. 18:1123-1129. doi:10.1038/mt.2010.67.
12. Diaz, R. M., et al. 2007. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res. 67:2840-2848. doi:10.1158/0008-5472.CAN-06-3974.
13. Friedl, P., and K. Wolf. 2003. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 3:362-374. doi:10.1038/nrc1075.
14. Garraway, L. A., and W. R. Sellers. 2006. Lineage dependency and lineagesurvival oncogenes in human cancer. Nat. Rev. Cancer 6:593-602. doi: 10.1038/nrc1947.
15. Gerlinger, M., and C. Swanton. 2010. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. Cancer 103:1139-1143. doi:10.1038/sj.bjc.6605912.
16. Hammill, A. M., J. Conner, and T. P. Cripe. 2010. Oncolytic virotherapy reaches adolescence. Pediatr. Blood Cancer 55:1253-1263. doi:10.1002/pbc.22724.
17. Held, M. A., et al. 2010. Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res. 70:388-397. doi:10.1158/0008-5472.CAN-09-2153.
18. Hingorani, P., et al. 2011. Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts. Cancer 117:1764-1774. doi: 10.1002/cncr.25741.
19. Jawad, M. U., M. C. Cheung, J. Clarke, L. G. Koniaris, and S. P. Scully. 2011. Osteosarcoma: improvement in survival limited to high-grade patients only. J. Cancer Res. Clin. Oncol. 137:597-607. doi:10.1007/s00432-010-0923-7.
20. Jemal, A., A. Thomas, T. Murray, and M. Thun. 2002. Cancer statistics, 2002. CA Cancer J. Clin. 52:23-47.
21. Lacroix, M. 2008. Persistent use of "false" cell lines. Int. J. Cancer 122:1-4. doi:10.1002/ijc.23233.
22. Leaman, D. W., A. Salvekar, R. Patel, G. C. Sen, and G. R. Stark. 1998. A mutant cell line defective in response to double-stranded RNA and in regulating basal expression of interferon-stimulated genes. Proc. Natl. Acad. Sci. U. S. A. 95:9442-9447.
23. Le Boeuf, F., et al. 2010. Synergistic interaction between oncolytic viruses augments tumor killing. Mol. Ther. 18:888-895. doi:10.1038/mt.2010.44.
24. Li, Q., M. Michaud, S. Canosa, A. Kuo, and J. A. Madri. 2011. GSK-3beta: a signaling pathway node modulating neural stem cell and endothelial cell interactions. Angiogenesis 14:173-185. doi:10.1007/s10456-011-9201-9.
25. Lichty, B. D., A. T. Power, D. F. Stojdl, and J. C. Bell. 2004. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol. Med. 10:210-216. doi: 10.1016/j.molmed.2004.03.003.
26. Liu, T. C., and D. Kirn. 2008. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther. 15:877-884. doi:10.1038/gt.2008.72.
27. Lockwood, C. J., et al. 2011. Decidual hemostasis, inflammation, and angiogenesis in pre-eclampsia. Semin. Thromb. Hemost. 37:158-164. doi:10.1055/s-0030-1270344.
28. Meager, A. 2002. Biological assays for interferons. J. Immunol. Methods 261:21-36.
29. Mitelman, F., B. Johansson, and F. Mertens. 2007. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 7:233-245. doi:10.1038/nrc2091.
30. Nguyen, T. L., et al. 2008. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl. Acad. Sci. U. S. A. 105:14981-14986. doi:10.1073/pnas.0803988105.
31. Oda, Y., and M. Tsuneyoshi. 2008. Recent advances in the molecular pathology of soft tissue sarcoma: implications for diagnosis, patient prognosis, and molecular target therapy in the future. Cancer Sci. 100:200-208. doi: 10.1111/j.1349-7006.2008.01024.x.
32. Otsuki, A., et al. 2008. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol. Ther. 16:1546-1555. doi: 10.1038/mt.2008.155.
33. Ozduman, K., G. Wollmann, J. M. Piepmeier, and A. N. van den Pol. 2008. Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J. Neurosci. 28:1882-1893. doi:10.1523/JNEUROSCI.4905-07.2008.
34. Randall, R. E., and S. Goodbourn. 2008. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 89:1-47. doi:10.1099/vir.0.83391-0.
35. Rouleau, C., et al. 2008. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin. Cancer Res. 14:7223-7236. doi:10.1158/1078-0432.CCR-08-0499.
36. Ryder, E. F., and P. Robakiewicz. 2001. Statistics for the molecular biologist: group comparisons. Curr. Protoc. Mol. Biol. Appendix 3I. doi:10.1002/0471142727.mba03is43.
37. Sadler, A. J., and B. R. Williams. 2008. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8:559-568. doi:10.1038/nri2314.
38. Sen, G. C., and S. N. Sarkar. 2007. The interferon-stimulated genes: targets of direct signaling by interferons, double-stranded RNA, and viruses. Curr. Top. Microbiol. Immunol. 316:233-250.
39. Stojdl, D. F., et al. 2000. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6:821-825. doi:10.1038/77558.
40. Stojdl, D. F., et al. 2003. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4:263- 275.
41. Taniguchi, T., and A. Takaoka. 2001. A weak signal for strong responses: interferon-alpha/beta revisited. Nat. Rev. Mol. Cell Biol. 2:378-386. doi: 10.1038/35073080.
42. Tomlinson, J., et al. 1999. Different patterns of angiogenesis in sarcomas and carcinomas. Clin. Cancer Res. 5:3516-3522.
43. van den Pol, A. N., K. P. Dalton, and J. K. Rose. 2002. Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J. Virol. 76:1309-1327.
44. van den Pol, A. N., et al. 2007. Cytomegalovirus induces interferon-stimulated gene expression and is attenuated by interferon in the developing brain. J. Virol. 81:332-348. doi:10.1128/JVI.01592-06.
45. Wang, J., et al. 2010. NF-kappa B RelA subunit is crucial for early IFN-beta expression and resistance to RNA virus replication. J. Immunol. 185:1720-1729. doi:10.4049/jimmunol.1000114.
46. Wollmann, G., M. D. Robek, and A. N. van den Pol. 2007. Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells. J. Virol. 81:1479-1491. doi:10.1128/JVI.01861-06.
47. Wollmann, G., V. Rogulin, I. Simon, J. K. Rose, and A. N. van den Pol. 2010. Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J. Virol. 84:1563-1573. doi:10.1128/JVI.02040-09.
48. Wollmann, G., P. Tattersall, and A. N. van den Pol. 2005. Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J. Virol. 79:6005-6022. doi:10.1128/JVI.79.10.6005-6022.2005.
49. Wongthida, P., et al. 2011. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum. Gene Ther. [Epub ahead of print.] doi:10.1089/hum.2010.216.
50. Zagars, G. K., et al. 2003. Prognostic factors for patients with localized soft tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 97:2530-2543. doi:10.1002/cncr.11365.